<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872674</url>
  </required_header>
  <id_info>
    <org_study_id>1-2018-0082</org_study_id>
    <nct_id>NCT03872674</nct_id>
  </id_info>
  <brief_title>A Trial Comparing High-flow Nasal Oxygen With Standard Management for Conscious Sedation During Endoscopic Retrograde Cholangiopancreatography in Prone Position</brief_title>
  <official_title>A Randomized Controlled Trial Comparing High-flow Nasal Oxygen With Standard Management for Conscious Sedation During Endoscopic Retrograde Cholangiopancreatography in Prone Position</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditional conscious sedation for endoscopic retrograde cholangiopancreatography in prone
      position places patients at risk of desaturation, and high-flow nasal oxygen may reduce the
      risk. The aim of this study is to evaluate the role of high-flow nasal oxygen during
      endoscopic retrograde cholangiopancreatography. The investigators will compare the lowest
      SpO2 of standard nasal oxygen cannula group and that of high-flow humidified oxygen-delivery
      system group during the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">April 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1: standard nasal cannula group Arm 2: high-flow humidified oxygen-delivery system (OptiFlow THRIVE) group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patients will be randomly allocated to 2 groups using computer-generated randomization method. Neither participants nor physicians will be blinded to the groups because of organizational reasons</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>lowest SpO2 measured with pulse oximetry during the procedure</measure>
    <time_frame>during the procedure (from the start to the end of the endoscopic retrograde cholangiopancreatography)</time_frame>
    <description>The investigators will record the lowest SpO2 during the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of desaturation below 90% during the procedure</measure>
    <time_frame>during the procedure (from the start to the end of the endoscopic retrograde cholangiopancreatography)</time_frame>
    <description>The investigators will compare the incidence of desaturation during the procedure between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Patients Undergoing Endoscopic Retrograde Cholangiopancreatography in Prone Position</condition>
  <arm_group>
    <arm_group_label>standard oxygenation(nasal cannula)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-flow humidified oxygen-delivery system(OptiFlow THRIVE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>high-flow humidified oxygen-delivery system (OptiFlow THRIVE)</intervention_name>
    <description>stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.</description>
    <arm_group_label>high-flow humidified oxygen-delivery system(OptiFlow THRIVE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. patients who will undergo endoscopic retrograde cholangiopancreatography under
             conscious sedation

        Exclusion Criteria:

          -  1. dementia or cognitive dysfunction

          -  2. altered mental status

          -  3. intubated patients or tracheostomy

          -  4. pregnancy

          -  5. recent history of nasal bleeding

          -  6. illiteracy or foreigner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

